Literature DB >> 33164635

Identification of HPV16-p16INK4a mediated methylation in oral potentially malignant disorder.

Maria Rosa Buenahora1, Gloria Inés Lafaurie2, Sandra J Perdomo3.   

Abstract

To evaluate the possible involvement of epigenetic modulation by HPV16-p16INK4a in oral potentially malignant disorder (OPMD). We generated DNA-methylation profiles, according to p16INK4a expression and HPV16 genotype (positive or negative), of OPMD samples and p16INK4a-HPV16 negative samples (used as control), using reduced-representation bisulphite sequencing (RRBS-Seq- Illumina) technology. Twelve samples, four for each group, as follows: 1) p16INK4a+ HPV16+; 2) p16INK4a+ HPV16-; 3) p16INK4a- HPV16-, were analysed in triplicate for DNA-methylation profiles. Fifty-four per cent of DMRs were hypermethylated and 46% were hypomethylated. An increase in methylation of loci in OPMD was independent of the presence of HPV. The hypermethylated genes in HPV+ samples were associated with signalling pathways such as NICD traffics to nucleus, signalling by NOTCH1 (p = 0.008), Interferon-gamma (p = 0.008) and Interleukin-6 signalling (p = 0.027). The hypomethylated genes in HPV infection were associated with TRAF3-dependent IRF activation pathway (p = 0.002), RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways (p = 0.005), TRAF6 mediated IRF7 activation (p = 0.009), TRIF-mediated TLR3/TLR4 signalling (p = 0.011) and MyD88-independent cascade release of apoptotic factors (p = 0.011). Protein association analysis of DMRs in OPMD revealed 19 genes involved in the cell cycle regulation, immune system, and focal adhesion. Aberrantly methylated loci in OPMD were observed in p16INK4a positive samples which suggests that a shift in global methylation status may be important for cancer progression. The results suggest that HPV infection in OPMD induces modulation of genes related to the immune system and regulation of the cellular cycle.

Entities:  

Keywords:  DNA-methylation; Oral potentially malignant disorder; RRBS; human papilloma virus; immune system

Mesh:

Substances:

Year:  2020        PMID: 33164635      PMCID: PMC8451454          DOI: 10.1080/15592294.2020.1834923

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  79 in total

1.  Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis.

Authors:  Maureen A Sartor; Dana C Dolinoy; Tamara R Jones; Justin A Colacino; Mark E P Prince; Thomas E Carey; Laura S Rozek
Journal:  Epigenetics       Date:  2011-06-01       Impact factor: 4.528

2.  Notch1 mutations are drivers of oral tumorigenesis.

Authors:  Evgeny Izumchenko; Kai Sun; Sian Jones; Mariana Brait; Nishant Agrawal; Wayne Koch; Christine L McCord; David R Riley; Samuel V Angiuoli; Victor E Velculescu; Wei-Wen Jiang; David Sidransky
Journal:  Cancer Prev Res (Phila)       Date:  2014-11-18

3.  Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia.

Authors:  Abhijit G Banerjee; Indraneel Bhattacharyya; Jamboor K Vishwanatha
Journal:  Mol Cancer Ther       Date:  2005-06       Impact factor: 6.261

4.  Unique DNA methylation loci distinguish anatomic site and HPV status in head and neck squamous cell carcinoma.

Authors:  Roberto A Lleras; Richard V Smith; Leslie R Adrien; Nicolas F Schlecht; Robert D Burk; Thomas M Harris; Geoffrey Childs; Michael B Prystowsky; Thomas J Belbin
Journal:  Clin Cancer Res       Date:  2013-07-26       Impact factor: 12.531

5.  Malignant transformation of oral leukoplakia: a retrospective cohort study of 218 Chinese patients.

Authors:  Wei Liu; Yu-Feng Wang; Hai-Wei Zhou; Peng Shi; Zeng-Tong Zhou; Guo-Yao Tang
Journal:  BMC Cancer       Date:  2010-12-16       Impact factor: 4.430

6.  Clinical impact of de-regulated Notch-1 and Notch-3 in the development and progression of HPV-associated different histological subtypes of precancerous and cancerous lesions of human uterine cervix.

Authors:  Richa Tripathi; Gayatri Rath; Poonam Jawanjal; Shweta Sharma; Pallavi Singhal; Suresh Bhambhani; Showket Hussain; Mausumi Bharadwaj
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.752

7.  Comprehensive genomic characterization of head and neck squamous cell carcinomas.

Authors: 
Journal:  Nature       Date:  2015-01-29       Impact factor: 49.962

8.  Downregulation of Ubiquitin-conjugating Enzyme UBE2D3 Promotes Telomere Maintenance and Radioresistance of Eca-109 Human Esophageal Carcinoma Cells.

Authors:  Hui Yang; Lin Wu; Shaobo Ke; Wenbo Wang; Lei Yang; Xiaojia Gao; Hongyan Fang; Haijun Yu; Yahua Zhong; Conghua Xie; Fuxiang Zhou; Yunfeng Zhou
Journal:  J Cancer       Date:  2016-06-06       Impact factor: 4.207

9.  Unique DNA methylation signature in HPV-positive head and neck squamous cell carcinomas.

Authors:  Davide Degli Esposti; Athena Sklias; Sheila C Lima; Stéphanie Beghelli-de la Forest Divonne; Vincent Cahais; Nora Fernandez-Jimenez; Marie-Pierre Cros; Szilvia Ecsedi; Cyrille Cuenin; Liacine Bouaoun; Graham Byrnes; Rosita Accardi; Anne Sudaka; Valérie Giordanengo; Hector Hernandez-Vargas; Luis Felipe Ribeiro Pinto; Ellen Van Obberghen-Schilling; Zdenko Herceg
Journal:  Genome Med       Date:  2017-04-05       Impact factor: 11.117

10.  Incorporation of differentiated dysplasia improves prediction of oral leukoplakia at increased risk of malignant progression.

Authors:  Leon J Wils; Jos B Poell; Ilkay Evren; Marit S Koopman; Elisabeth R E A Brouns; Jan G A M de Visscher; Ruud H Brakenhoff; Elisabeth Bloemena
Journal:  Mod Pathol       Date:  2020-01-02       Impact factor: 7.842

View more
  1 in total

1.  Detecting Early-Stage Oral Cancer from Clinically Diagnosed Oral Potentially Malignant Disorders by DNA Methylation Profile.

Authors:  Kazuki Mori; Tomofumi Hamada; Mahiro Beppu; Hiroki Tsuchihashi; Yuichi Goto; Kenichi Kume; Hiroshi Hijioka; Keitaro Nishi; Yumiko Mishima; Tsuyoshi Sugiura
Journal:  Cancers (Basel)       Date:  2022-05-26       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.